• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC HEART VALVES DIVISION MOSAIC MITRAL BIOPROSTHETIC HEART VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC HEART VALVES DIVISION MOSAIC MITRAL BIOPROSTHETIC HEART VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Model Number 310C
Device Problems Hole In Material (1293); Incomplete Coaptation (2507)
Patient Problem No Code Available (3191)
Event Date 02/17/2017
Event Type  Injury  
Manufacturer Narrative
The device has not been received for analysis.Without the receipt of the product, no definitive conclusion can be made regarding the clinical observation.Additional information has been requested, but no new information has been received to date.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Medtronic received information one year, nine months following the implant this bioprosthetic valve, this valve was explanted due to clot formation on the ventricular side, which was causing the leaflet to not close, and a leaflet hole.Prior to the replacement procedure, the patient was symptomatic.No other adverse patient effects were reported.
 
Manufacturer Narrative
Medtronic received additional information that this device was implanted for one year, six months, and not one year, nine months as initially indicated.
 
Manufacturer Narrative
Product analysis: upon receipt at medtronic¿s quality laboratory, pieces of the sewing ring, host tissue and pledgets were received with the valve for analysis.The valve appeared distorted; oval shaped.Two pledgets remained attached to the sewing ring on the inflow.The non-coronary and left cusps were stiff due to host tissue on the outflow.The left cusp appeared slightly stiff but flexible.All leaflets appeared intact.The free margin of the left cusp appeared to fold back and adhere to the host tissue on the outflow.All commissures appeared intact.Traces of pannus remained attached to the sewing ring on the inflow.Remnants of pannus were observed on the outflow rail adjacent to the right and non-coronary cusps, extending to the commissural area, partially covering the top of the commissure and slightly onto the free margins.Tan to brown thrombotic appearing host tissue filled and stiffened the non-coronary and left cusps on the outflow.An unknown amount of pannus appeared to have been removed on the inflow and/or outflow during explant.Radiography showed no evidence of mineralization on the valve and/or host tissue.Conclusion: the device history record was reviewed and showed that this product met all manufacturing specifications for product released for distribution.No issues were identified that would have impacted this event.A visual examination of the returned device was performed upon receipt.The device was distorted (oval shaped).The reported "leaflet hole" was not observed; it could have referred to the gaps between the leaflets.An unknown amount of pannus appeared to be removed on the inflow and outflow during explant.The pannus overgrowth on the inflow / outflow could have significantly impaired the leaflet mobility.The impairment of leaflet mobility may have led to the thrombus formation on the outflow of the valve causing the leaflet coaptation issue.Distortion of the annular ring can also restrict the leaflets from fully opening and potentially affecting the coaptation.Pannus overgrowth is associated with surgical valve replacement due to patient interaction and/or healing response with the surgical valve.Pannus overgrowth has been an inherent risk of surgical valve replacement.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MOSAIC MITRAL BIOPROSTHETIC HEART VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer (Section G)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer Contact
paula bixby
8200 coral sea street ne
mounds view, MN 55112
7635055378
MDR Report Key6407276
MDR Text Key70016472
Report Number2025587-2017-00405
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P990064
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial,Followup,Followup,Followup,Followup
Report Date 10/17/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/15/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date05/16/2020
Device Model Number310C
Device Catalogue Number310C27
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer03/29/2017
Is the Reporter a Health Professional? Yes
Date Manufacturer Received06/12/2017
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured05/18/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age69 YR
-
-